Literature DB >> 7489951

'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis.

A D Dwarakanath1, L G Yu, C Brookes, D Pryce, J M Rhodes.   

Abstract

Pyoderma gangrenosum is strongly associated with inflammatory bowel disease and exhibits pathergy, occurring at sites of previous minor trauma. A patient is presented with a 21 year history of extensive ulcerative colitis, who developed pyoderma gangrenosum and arthralgia while receiving high dose corticosteroids for active ulcerative colitis. The arthralgia exhibited pathergy affecting particularly the left temporomandibular joint, which was stressed by an asymmetric bite, and the left elbow, which had been fractured many years previously. This prompted the hypothesis that neutrophils in this condition may be marginated, as a result of increased stickiness of either the neutrophil or the vascular endothelium. The introduction of heparin therapy was associated with rapid resolution of the arthralgia, pyoderma gangrenosum, and ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489951      PMCID: PMC1382916          DOI: 10.1136/gut.37.4.585

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  Polymorphonuclear leucocytes in Crohn's disease and ulcerative proctocolitis: association between enhanced adherence to nylon fibre and disease variables.

Authors:  J Cason; C C Ainley; R A Wolstencroft; R P Thompson
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

2.  Pyoderma gangrenosum.

Authors:  A D Walling; D Sweet
Journal:  Am Fam Physician       Date:  1987-01       Impact factor: 3.292

3.  Pyoderma gangrenosum after colectomy for inflammatory bowel disease. Case report.

Authors:  D E Holmlund; L Wählby
Journal:  Acta Chir Scand       Date:  1987-01

4.  Treatment of pyoderma gangrenosum with disodium cromoglycate.

Authors:  B Saffouri; B M Hom; J M Mertesdorf; J E Gardiner
Journal:  Dig Dis Sci       Date:  1984-02       Impact factor: 3.199

5.  [Use of anticoagulants in the combined treatment of nonspecific ulcerative colitis].

Authors:  L G Zavgorodniĭ; A P Mustiats
Journal:  Klin Med (Mosk)       Date:  1982-06

6.  Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response.

Authors:  J I Gallin; M P Fletcher; B E Seligmann; S Hoffstein; K Cehrs; N Mounessa
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

7.  Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.

Authors:  O Lider; E Baharav; Y A Mekori; T Miller; Y Naparstek; I Vlodavsky; I R Cohen
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

8.  Pyoderma gangrenosum: a review of 86 patients.

Authors:  F C Powell; A L Schroeter; W P Su; H O Perry
Journal:  Q J Med       Date:  1985-05

9.  Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro.

Authors:  G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

10.  Pyoderma gangrenosum and erosive peripheral arthritis.

Authors:  H J Griffiths; M Sundaram
Journal:  Can Assoc Radiol J       Date:  1986-06       Impact factor: 2.248

View more
  8 in total

1.  An exuberant inflammatory response to E coli: implications for the pathogenesis of ulcerative colitis and pyoderma gangrenosum.

Authors:  D J B Marks; F Z Rahman; M Novelli; R C Yu; S McCartney; S Bloom; A W Segal
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

2.  Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin.

Authors:  Małgorzata Sobieszczańska; Sławomir Tubek; Ilona Kura
Journal:  Hum Vaccin Immunother       Date:  2014-01-17       Impact factor: 3.452

3.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

4.  Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism.

Authors:  A Salas; M Sans; A Soriano; J C Reverter; D C Anderson; J M Piqué; J Panés
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

Review 5.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 6.  Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Expert Opin Investig Drugs       Date:  2008-04       Impact factor: 6.206

7.  Pathergy in non-Hodgkin lymphoma.

Authors:  Ikram A Burney; Tariq Moatter; Tariq Siddiqui; Nausheen Yaqoob
Journal:  J R Soc Med       Date:  2003-03       Impact factor: 18.000

8.  Improvement of Ulcerations in Treatment-Resistant Chronic Scarring in a Patient with Pyoderma Gangrenosum After Improving Vascular Insufficiency, Gently Removing Necrotic Debris, and Decreasing Wound Fluid.

Authors:  William J Nahm; Jorge A Mota; Sarah Rojas; Brian J Hizon; Chris Gordon
Journal:  Am J Case Rep       Date:  2018-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.